What's Happening?
Evinature's CurQD Protocol has been officially included in the 2025 ECCO Guidelines on Dietary Management of Inflammatory Bowel Disease (IBD), marking a significant advancement in integrative care for ulcerative colitis and Crohn's disease. The European
Crohn’s and Colitis Organisation (ECCO) recognized CurQD as a potential adjunct dietary approach based on scientific evidence. This inclusion follows the protocol's presentation at the ECCO Congress in Berlin, where it was highlighted for its evidence-backed outcomes. The ECCO Guidelines are a trusted reference in gastroenterology, guiding clinicians worldwide in IBD management.
Why It's Important?
The inclusion of CurQD in the ECCO Guidelines represents a major step forward for patients seeking natural, evidence-based treatment options for IBD. It validates years of research and highlights the potential for integrative approaches to complement conventional IBD care. The guidelines' recognition positions CurQD as a credible option within the standard of care, offering patients and physicians a validated natural therapy. This development underscores the growing acceptance of integrative approaches in medical practice, potentially improving patient outcomes and supporting long-term remission.
What's Next?
With its inclusion in the ECCO Guidelines, CurQD is poised to become a standard part of IBD management strategies. Future research may focus on further validating its efficacy and exploring additional applications in other chronic conditions. The recognition may also encourage more healthcare providers to consider integrative therapies in their practice, potentially leading to broader acceptance and use of natural interventions in clinical settings. As Evinature continues to advance its mission, the company may explore new partnerships and research opportunities to expand the reach and impact of its protocols.
